The hypoxic tumour microenvironment, patient... (2007 study) Skip to main content
Prospective Study Clinical oncology (Royal College of Radiologists (Great Britain)) 2007

The hypoxic tumour microenvironment, patient selection and hypoxia-modifying treatments.

Hoogsteen IJ, Marres HA, van der Kogel AJ, Kaanders JH, Clinical oncology (Royal College of Radiologists (Great Britain)), 2007

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

The authors reviewed published studies on low oxygen in tumours, how it is measured, how patients are chosen for treatments aimed at it, and ways to overcome it during treatment.

What They Found

This review of published studies describes tumour hypoxia as a feature of many solid tumours that decreases the effectiveness of radiation treatment, surgery and some forms of chemotherapy. Approaches to counteract this resistance have been developed, but usually at the cost of increased short- and long-term side-effects. New methods for measuring tumour oxygen have made it possible to establish the prognostic significance of hypoxia. Several genes and proteins involved in the response to hypoxia have been identified as possible candidates for future predictive tests. Some markers and combinations have shown potential benefit and are associated with treatment outcome, but their clinical usefulness needs to be validated in prospective trials.

What This Means for Canadian Patients

For people with solid tumours, the abstract says that measuring how much of a tumour is low in oxygen may help select patients for hypoxia-modifying treatments. The abstract does not describe hyperbaric oxygen therapy, its results, or whether it should be used, so it gives no guidance on HBOT. Patients with questions about their own cancer treatment should speak with their oncology team.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

The abstract describes a review of published studies rather than new patient data, and it states that the predictive markers still need validation in prospective trials before their clinical usefulness is known.

This plain-language summary was generated with AI assistance from the study's abstract; it has not been individually reviewed by a clinician. Always consult the source study and a qualified healthcare professional. See our editorial policy.

Was this summary helpful?

Study Details

Study Type Prospective Study
Category Radiation Injury
Source Pubmed
PubMed ID 17433637
Year Published 2007
Journal Clinical oncology (Royal College of Radiologists (Great Britain))
MeSH Terms Anemia; Biomarkers, Tumor; Carbon Dioxide; Cell Hypoxia; Humans; Hyperbaric Oxygenation; Neoplasms; Niacinamide; Nuclear Medicine; Oxygen; Patient Selection; Radiation Tolerance; Radiation-Sensitizing Agents; Vitamin B Complex

Cite This Study

Share

This study relates to Delayed Radiation Injury. Read the full clinical overview, the evidence base, and Canadian treatment access for this condition.

Find a Canadian Clinic Treating Radiation Injury

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last updated: April 1, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology